(Q44685789)

5 December 2017

title

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy (English)

1 reference

5 December 2017

1 reference

D Teitelbaum

1

1 reference

5 December 2017

T Brenner

2

1 reference

5 December 2017

O Abramsky

3

1 reference

5 December 2017

R Aharoni

4

1 reference

5 December 2017

M Sela

5

1 reference

5 December 2017

R Arnon

6

1 reference

5 December 2017

publication date

1 December 2003

1 reference

Multiple Sclerosis Journal

5 December 2017

published in

1 reference

5 December 2017

volume

9

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

592-599

1 reference

Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Immunological aspects of demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Major T-cell responses in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Considerations in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Automated Synthesis of Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

In vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)‐A–L

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS963OA

10.1191/1352458503MS963OA

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference